Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BDTX-1535 in Recurrent High-Grade Glioma and Newly Diagnosed Glioblastoma
NCT06072586Phase 1Recruiting
- Sponsor
- St. Joseph's Hospital and Medical Center
- Start
- Oct 2023
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of silevertinib in glioma and glioblastoma (GBM) (5 arms), sponsored by St. Joseph's Hospital and Medical Center. Primary endpoints: Unbound BDTX-1535 Concentration in Tumor Tissue, Total BDTX-1535 Concentration in Tumor Tissue and 4 more. Started Oct 2023; status: recruiting.
02
Drugs
silevertinib
03
Conditions
gliomaglioblastoma (GBM)
Beyond the preview
Go deeper on NCT06072586.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06072586.